E Donnelly Selected Research

Vascular Tissue Neoplasms

3/2001

Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

E Donnelly Research Topics

Disease

2	Neoplasms (Cancer) 04/2016 - 03/2001
1	Type 2 Diabetes Mellitus (MODY) 01/2016
1	Diabetes Complications 01/2016
1	Atrophy 01/2004
1	Muscular Atrophy (Muscle Atrophy) 01/2004
1	Prostatic Neoplasms (Prostate Cancer) 07/2003
1	Melanoma (Melanoma, Malignant) 03/2001
1	Vascular Tissue Neoplasms 03/2001

Drug/Important Bio-Agent (IBA)

1	CrizotinibIBA 04/2016
1	Insulin (Novolin)FDA Link 01/2016
1	sauvagineIBA 01/2004
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2004
1	Prednisone (Sone)FDA LinkGeneric 07/2003
1	Vinorelbine (Navelbine)FDA LinkGeneric 07/2003
1	Hormones (Hormone)IBA 07/2003
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 03/2001
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 03/2001
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/2001
1	Semaxinib (SU5416)IBA 03/2001

Therapy/Procedure

2	Therapeutics 01/2016 - 03/2001
1	Adrenalectomy 01/2004
1	Radiotherapy 03/2001
1	Aftercare (After-Treatment) 03/2001